nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—RRM1—multiple sclerosis	0.673	1	CbGaD
Cladribine—ABCG2—Mitoxantrone—multiple sclerosis	0.0159	0.517	CbGbCtD
Cladribine—RRM2B—Nucleotide Metabolism—SRM—multiple sclerosis	0.00976	0.123	CbGpPWpGaD
Cladribine—ABCG2—Dexamethasone—multiple sclerosis	0.00826	0.268	CbGbCtD
Cladribine—ABCG2—Methotrexate—multiple sclerosis	0.00664	0.215	CbGbCtD
Cladribine—RRM2B—Synthesis and interconversion of nucleotide di- and triphosphates—RRM1—multiple sclerosis	0.00544	0.0685	CbGpPWpGaD
Cladribine—RRM2B—Nucleotide Metabolism—RRM1—multiple sclerosis	0.00521	0.0656	CbGpPWpGaD
Cladribine—RRM1—Nucleotide Metabolism—SRM—multiple sclerosis	0.00486	0.0612	CbGpPWpGaD
Cladribine—RRM2—Nucleotide Metabolism—SRM—multiple sclerosis	0.004	0.0504	CbGpPWpGaD
Cladribine—POLA1—Nucleotide Metabolism—SRM—multiple sclerosis	0.00274	0.0345	CbGpPWpGaD
Cladribine—POLE4—nervous system—multiple sclerosis	0.00251	0.0439	CbGeAlD
Cladribine—POLE4—central nervous system—multiple sclerosis	0.00241	0.0423	CbGeAlD
Cladribine—NR5A1—brainstem—multiple sclerosis	0.00225	0.0394	CbGeAlD
Cladribine—RRM2—Synthesis and interconversion of nucleotide di- and triphosphates—RRM1—multiple sclerosis	0.00223	0.0281	CbGpPWpGaD
Cladribine—RRM2—Nucleotide Metabolism—RRM1—multiple sclerosis	0.00214	0.0269	CbGpPWpGaD
Cladribine—POLE4—brain—multiple sclerosis	0.00192	0.0336	CbGeAlD
Cladribine—Clofarabine—RRM1—multiple sclerosis	0.00188	0.508	CrCbGaD
Cladribine—Fludarabine—RRM1—multiple sclerosis	0.00182	0.492	CrCbGaD
Cladribine—RRM2B—medulla oblongata—multiple sclerosis	0.00171	0.03	CbGeAlD
Cladribine—RRM2B—Nucleotide metabolism—RRM1—multiple sclerosis	0.00168	0.0212	CbGpPWpGaD
Cladribine—POLE3—medulla oblongata—multiple sclerosis	0.00162	0.0283	CbGeAlD
Cladribine—RRM2B—midbrain—multiple sclerosis	0.00156	0.0274	CbGeAlD
Cladribine—RRM2B—spinal cord—multiple sclerosis	0.00153	0.0267	CbGeAlD
Cladribine—POLE3—midbrain—multiple sclerosis	0.00148	0.0259	CbGeAlD
Cladribine—POLA1—retina—multiple sclerosis	0.00147	0.0258	CbGeAlD
Cladribine—POLA1—Nucleotide Metabolism—RRM1—multiple sclerosis	0.00146	0.0184	CbGpPWpGaD
Cladribine—PNP—Nucleotide metabolism—RRM1—multiple sclerosis	0.00146	0.0184	CbGpPWpGaD
Cladribine—POLE3—spinal cord—multiple sclerosis	0.00144	0.0253	CbGeAlD
Cladribine—PNP—nervous system—multiple sclerosis	0.00139	0.0243	CbGeAlD
Cladribine—RRM2—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.00137	0.0173	CbGpPWpGaD
Cladribine—NR5A1—Ovarian Infertility Genes—PGR—multiple sclerosis	0.00137	0.0172	CbGpPWpGaD
Cladribine—PNP—central nervous system—multiple sclerosis	0.00133	0.0234	CbGeAlD
Cladribine—RRM2B—nervous system—multiple sclerosis	0.00129	0.0225	CbGeAlD
Cladribine—RRM2B—central nervous system—multiple sclerosis	0.00124	0.0217	CbGeAlD
Cladribine—POLE3—nervous system—multiple sclerosis	0.00122	0.0213	CbGeAlD
Cladribine—RRM2B—cerebellum—multiple sclerosis	0.00121	0.0212	CbGeAlD
Cladribine—NR5A1—Nuclear Receptors—PGR—multiple sclerosis	0.00119	0.015	CbGpPWpGaD
Cladribine—NR5A1—nervous system—multiple sclerosis	0.00118	0.0206	CbGeAlD
Cladribine—POLE3—central nervous system—multiple sclerosis	0.00117	0.0205	CbGeAlD
Cladribine—RRM1—retina—multiple sclerosis	0.00117	0.0205	CbGeAlD
Cladribine—POLE3—cerebellum—multiple sclerosis	0.00114	0.02	CbGeAlD
Cladribine—NR5A1—central nervous system—multiple sclerosis	0.00113	0.0199	CbGeAlD
Cladribine—NR5A1—cerebellum—multiple sclerosis	0.00111	0.0194	CbGeAlD
Cladribine—PNP—brain—multiple sclerosis	0.00106	0.0186	CbGeAlD
Cladribine—RRM2B—brain—multiple sclerosis	0.000983	0.0172	CbGeAlD
Cladribine—NR5A1—Ovarian Infertility Genes—VDR—multiple sclerosis	0.000955	0.012	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000943	0.0119	CbGpPWpGaD
Cladribine—NR5A1—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.000942	0.0119	CbGpPWpGaD
Cladribine—POLE3—brain—multiple sclerosis	0.000929	0.0163	CbGeAlD
Cladribine—POLE—nervous system—multiple sclerosis	0.000927	0.0162	CbGeAlD
Cladribine—SLC22A2—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—multiple sclerosis	0.000908	0.0114	CbGpPWpGaD
Cladribine—DCK—retina—multiple sclerosis	0.000908	0.0159	CbGeAlD
Cladribine—NR5A1—brain—multiple sclerosis	0.0009	0.0158	CbGeAlD
Cladribine—POLE—central nervous system—multiple sclerosis	0.000893	0.0156	CbGeAlD
Cladribine—POLE—cerebellum—multiple sclerosis	0.000873	0.0153	CbGeAlD
Cladribine—SLC22A1—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—multiple sclerosis	0.000846	0.0107	CbGpPWpGaD
Cladribine—RRM1—medulla oblongata—multiple sclerosis	0.000844	0.0148	CbGeAlD
Cladribine—NR5A1—Nuclear Receptors—VDR—multiple sclerosis	0.000833	0.0105	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—IRF5—multiple sclerosis	0.000786	0.0099	CbGpPWpGaD
Cladribine—RRM1—midbrain—multiple sclerosis	0.000772	0.0135	CbGeAlD
Cladribine—RRM2—nervous system—multiple sclerosis	0.000764	0.0134	CbGeAlD
Cladribine—RRM1—spinal cord—multiple sclerosis	0.000753	0.0132	CbGeAlD
Cladribine—POLA1—cerebellum—multiple sclerosis	0.000752	0.0132	CbGeAlD
Cladribine—RRM2—central nervous system—multiple sclerosis	0.000735	0.0129	CbGeAlD
Cladribine—RRM2—E2F transcription factor network—RRM1—multiple sclerosis	0.000728	0.00917	CbGpPWpGaD
Cladribine—POLE—brain—multiple sclerosis	0.000709	0.0124	CbGeAlD
Cladribine—RRM2B—DNA Damage Response—FAS—multiple sclerosis	0.000707	0.00891	CbGpPWpGaD
Cladribine—RRM2—Nucleotide metabolism—RRM1—multiple sclerosis	0.000691	0.0087	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—FAS—multiple sclerosis	0.000683	0.00861	CbGpPWpGaD
Cladribine—NR5A1—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.000658	0.00829	CbGpPWpGaD
Cladribine—DCK—medulla oblongata—multiple sclerosis	0.000656	0.0115	CbGeAlD
Cladribine—DCK—Nucleotide metabolism—RRM1—multiple sclerosis	0.000645	0.00813	CbGpPWpGaD
Cladribine—RRM1—nervous system—multiple sclerosis	0.000635	0.0111	CbGeAlD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000633	0.00797	CbGpPWpGaD
Cladribine—POLA1—brain—multiple sclerosis	0.000611	0.0107	CbGeAlD
Cladribine—RRM1—central nervous system—multiple sclerosis	0.000611	0.0107	CbGeAlD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000607	0.00765	CbGpPWpGaD
Cladribine—DCK—midbrain—multiple sclerosis	0.0006	0.0105	CbGeAlD
Cladribine—RRM1—cerebellum—multiple sclerosis	0.000597	0.0105	CbGeAlD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000591	0.00745	CbGpPWpGaD
Cladribine—ABCG2—Irinotecan Pathway—BCHE—multiple sclerosis	0.000586	0.00738	CbGpPWpGaD
Cladribine—DCK—spinal cord—multiple sclerosis	0.000585	0.0102	CbGeAlD
Cladribine—RRM2—brain—multiple sclerosis	0.000584	0.0102	CbGeAlD
Cladribine—NR5A1—Transcriptional regulation of pluripotent stem cells—STAT3—multiple sclerosis	0.000572	0.00721	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—CD24—multiple sclerosis	0.000569	0.00717	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000557	0.00702	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.000539	0.00679	CbGpPWpGaD
Cladribine—ABCG2—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.000514	0.00647	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—RRM1—multiple sclerosis	0.000498	0.00627	CbGpPWpGaD
Cladribine—SLC28A3—Transport of vitamins, nucleosides, and related molecules—ALB—multiple sclerosis	0.000495	0.00623	CbGpPWpGaD
Cladribine—DCK—nervous system—multiple sclerosis	0.000493	0.00863	CbGeAlD
Cladribine—RRM1—brain—multiple sclerosis	0.000485	0.0085	CbGeAlD
Cladribine—DCK—central nervous system—multiple sclerosis	0.000475	0.00831	CbGeAlD
Cladribine—DCK—cerebellum—multiple sclerosis	0.000464	0.00813	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—VDR—multiple sclerosis	0.000455	0.00573	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000433	0.00545	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000422	0.00532	CbGpPWpGaD
Cladribine—SLC22A1—nervous system—multiple sclerosis	0.00042	0.00736	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—SPP1—multiple sclerosis	0.000412	0.00518	CbGpPWpGaD
Cladribine—SLC22A1—central nervous system—multiple sclerosis	0.000405	0.00709	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—FAS—multiple sclerosis	0.000397	0.005	CbGpPWpGaD
Cladribine—DCK—brain—multiple sclerosis	0.000377	0.0066	CbGeAlD
Cladribine—ABCG2—medulla oblongata—multiple sclerosis	0.000366	0.00641	CbGeAlD
Cladribine—ABCG2—midbrain—multiple sclerosis	0.000334	0.00586	CbGeAlD
Cladribine—ABCG2—spinal cord—multiple sclerosis	0.000326	0.00572	CbGeAlD
Cladribine—RRM2B—DNA Damage Response—MYC—multiple sclerosis	0.000322	0.00406	CbGpPWpGaD
Cladribine—SLC22A1—brain—multiple sclerosis	0.000321	0.00563	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—MYC—multiple sclerosis	0.000312	0.00392	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000295	0.00372	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—SRM—multiple sclerosis	0.000286	0.00361	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000283	0.00357	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—ZNF746—multiple sclerosis	0.00026	0.00327	CbGpPWpGaD
Cladribine—ABCG2—cerebellum—multiple sclerosis	0.000259	0.00453	CbGeAlD
Cladribine—PNP—Metabolism—SRM—multiple sclerosis	0.000248	0.00313	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—PTBP1—multiple sclerosis	0.000237	0.00299	CbGpPWpGaD
Cladribine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000231	0.00291	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000231	0.00291	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000224	0.00283	CbGpPWpGaD
Cladribine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000215	0.00271	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000215	0.0027	CbGpPWpGaD
Cladribine—ABCG2—brain—multiple sclerosis	0.00021	0.00368	CbGeAlD
Cladribine—RRM2B—Metabolism—CYP27B1—multiple sclerosis	0.000202	0.00254	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CYP24A1—multiple sclerosis	0.000202	0.00254	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—MYC—multiple sclerosis	0.000197	0.00248	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—KCNA3—multiple sclerosis	0.000189	0.00238	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—PRNP—multiple sclerosis	0.000188	0.00237	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GPC5—multiple sclerosis	0.000185	0.00232	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.00018	0.00227	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—HNRNPA1—multiple sclerosis	0.00018	0.00227	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—U2AF2—multiple sclerosis	0.00018	0.00227	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—KCNA3—multiple sclerosis	0.000176	0.00222	CbGpPWpGaD
Cladribine—PNP—Metabolism—CYP27B1—multiple sclerosis	0.000175	0.0022	CbGpPWpGaD
Cladribine—PNP—Metabolism—CYP24A1—multiple sclerosis	0.000175	0.0022	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.00017	0.00214	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—PGR—multiple sclerosis	0.000163	0.00205	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	0.000162	0.00204	CbGpPWpGaD
Cladribine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	0.000161	0.00203	CbGpPWpGaD
Cladribine—PNP—Metabolism—GPC5—multiple sclerosis	0.00016	0.00202	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000154	0.00194	CbGpPWpGaD
Cladribine—PNP—Clobetasol propionate—Methylprednisolone—multiple sclerosis	0.000154	0.0381	CbGdCrCtD
Cladribine—RRM2B—Metabolism—RRM1—multiple sclerosis	0.000153	0.00193	CbGpPWpGaD
Cladribine—PNP—Flunisolide—Methylprednisolone—multiple sclerosis	0.000152	0.0376	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Betamethasone—multiple sclerosis	0.000152	0.0375	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Dexamethasone—multiple sclerosis	0.000152	0.0375	CbGdCrCtD
Cladribine—RRM1—E2F transcription factor network—MYC—multiple sclerosis	0.000152	0.00191	CbGpPWpGaD
Cladribine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	0.00015	0.00189	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.00015	0.00189	CbGpPWpGaD
Cladribine—PNP—Flunisolide—Betamethasone—multiple sclerosis	0.00015	0.037	CbGdCrCtD
Cladribine—PNP—Flunisolide—Dexamethasone—multiple sclerosis	0.00015	0.037	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Triamcinolone—multiple sclerosis	0.000148	0.0366	CbGdCrCtD
Cladribine—PNP—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000147	0.0363	CbGdCrCtD
Cladribine—PNP—Flunisolide—Triamcinolone—multiple sclerosis	0.000146	0.0361	CbGdCrCtD
Cladribine—NR5A1—Developmental Biology—PTPRC—multiple sclerosis	0.000146	0.00184	CbGpPWpGaD
Cladribine—PNP—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000145	0.0357	CbGdCrCtD
Cladribine—PNP—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000145	0.0357	CbGdCrCtD
Cladribine—RRM1—Metabolism—SRM—multiple sclerosis	0.000143	0.0018	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—ZFP36L1—multiple sclerosis	0.000142	0.00179	CbGpPWpGaD
Cladribine—PNP—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000141	0.0349	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Prednisone—multiple sclerosis	0.000141	0.0347	CbGdCrCtD
Cladribine—PNP—Flunisolide—Prednisone—multiple sclerosis	0.000139	0.0343	CbGdCrCtD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000138	0.00174	CbGpPWpGaD
Cladribine—PNP—Fluocinolone Acetonide—Methylprednisolone—multiple sclerosis	0.000138	0.0342	CbGdCrCtD
Cladribine—PNP—Clobetasol propionate—Prednisolone—multiple sclerosis	0.000137	0.0339	CbGdCrCtD
Cladribine—PNP—Fluocinolone Acetonide—Dexamethasone—multiple sclerosis	0.000136	0.0336	CbGdCrCtD
Cladribine—PNP—Fluocinolone Acetonide—Betamethasone—multiple sclerosis	0.000136	0.0336	CbGdCrCtD
Cladribine—PNP—Flunisolide—Prednisolone—multiple sclerosis	0.000136	0.0335	CbGdCrCtD
Cladribine—POLE2—G1/S Transition—MYC—multiple sclerosis	0.000135	0.0017	CbGpPWpGaD
Cladribine—PNP—Fluocinolone Acetonide—Triamcinolone—multiple sclerosis	0.000133	0.0329	CbGdCrCtD
Cladribine—PNP—Metabolism—RRM1—multiple sclerosis	0.000133	0.00167	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	0.000132	0.00166	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000129	0.00162	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—MYC—multiple sclerosis	0.000127	0.0016	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000126	0.00159	CbGpPWpGaD
Cladribine—RRM2—E2F transcription factor network—MYC—multiple sclerosis	0.000125	0.00157	CbGpPWpGaD
Cladribine—PNP—Fluocinolone Acetonide—Prednisolone—multiple sclerosis	0.000123	0.0304	CbGdCrCtD
Cladribine—POLE2—S Phase—MYC—multiple sclerosis	0.000123	0.00154	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SRM—multiple sclerosis	0.000117	0.00148	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—MYC—multiple sclerosis	0.000114	0.00143	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—VDR—multiple sclerosis	0.000114	0.00143	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—PABPC1—multiple sclerosis	0.00011	0.00139	CbGpPWpGaD
Cladribine—DCK—Metabolism—SRM—multiple sclerosis	0.00011	0.00138	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	0.000109	0.00137	CbGpPWpGaD
Cladribine—Anxiety—Methylprednisolone—multiple sclerosis	0.000108	0.000715	CcSEcCtD
Cladribine—Infestation—Methotrexate—multiple sclerosis	0.000108	0.000713	CcSEcCtD
Cladribine—Infestation NOS—Methotrexate—multiple sclerosis	0.000108	0.000713	CcSEcCtD
Cladribine—Rash—Azathioprine—multiple sclerosis	0.000108	0.000712	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000108	0.000712	CcSEcCtD
Cladribine—Dermatitis—Azathioprine—multiple sclerosis	0.000108	0.000712	CcSEcCtD
Cladribine—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000108	0.000711	CcSEcCtD
Cladribine—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000108	0.000711	CcSEcCtD
Cladribine—Discomfort—Triamcinolone—multiple sclerosis	0.000108	0.00071	CcSEcCtD
Cladribine—Discomfort—Methylprednisolone—multiple sclerosis	0.000107	0.000709	CcSEcCtD
Cladribine—Headache—Azathioprine—multiple sclerosis	0.000107	0.000708	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000107	0.000707	CcSEcCtD
Cladribine—PNP—Danazol—Prednisone—multiple sclerosis	0.000106	0.0263	CbGdCrCtD
Cladribine—Renal failure—Methotrexate—multiple sclerosis	0.000106	0.000701	CcSEcCtD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000106	0.00134	CbGpPWpGaD
Cladribine—Angiopathy—Prednisone—multiple sclerosis	0.000105	0.000695	CcSEcCtD
Cladribine—Conjunctivitis—Methotrexate—multiple sclerosis	0.000105	0.000694	CcSEcCtD
Cladribine—Confusional state—Methylprednisolone—multiple sclerosis	0.000105	0.000693	CcSEcCtD
Cladribine—Immune system disorder—Prednisone—multiple sclerosis	0.000105	0.000692	CcSEcCtD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000105	0.00132	CbGpPWpGaD
Cladribine—Malaise—Dexamethasone—multiple sclerosis	0.000105	0.000691	CcSEcCtD
Cladribine—Malaise—Betamethasone—multiple sclerosis	0.000105	0.000691	CcSEcCtD
Cladribine—Oedema—Triamcinolone—multiple sclerosis	0.000104	0.000689	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	0.000104	0.00131	CbGpPWpGaD
Cladribine—Arrhythmia—Prednisone—multiple sclerosis	0.000104	0.000685	CcSEcCtD
Cladribine—Infection—Triamcinolone—multiple sclerosis	0.000104	0.000685	CcSEcCtD
Cladribine—Infection—Methylprednisolone—multiple sclerosis	0.000104	0.000683	CcSEcCtD
Cladribine—Insomnia—Prednisolone—multiple sclerosis	0.000103	0.000678	CcSEcCtD
Cladribine—Alopecia—Prednisone—multiple sclerosis	0.000103	0.000677	CcSEcCtD
Cladribine—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000102	0.000675	CcSEcCtD
Cladribine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000102	0.000674	CcSEcCtD
Cladribine—Epistaxis—Methotrexate—multiple sclerosis	0.000102	0.000673	CcSEcCtD
Cladribine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000102	0.000673	CcSEcCtD
Cladribine—Paraesthesia—Prednisolone—multiple sclerosis	0.000102	0.000673	CcSEcCtD
Cladribine—Tachycardia—Triamcinolone—multiple sclerosis	0.000102	0.000673	CcSEcCtD
Cladribine—Mental disorder—Prednisone—multiple sclerosis	0.000102	0.000671	CcSEcCtD
Cladribine—Nausea—Azathioprine—multiple sclerosis	0.000102	0.000671	CcSEcCtD
Cladribine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000102	0.000671	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000101	0.00128	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	0.000101	0.00128	CbGpPWpGaD
Cladribine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000101	0.000668	CcSEcCtD
Cladribine—Erythema—Prednisone—multiple sclerosis	0.000101	0.000667	CcSEcCtD
Cladribine—Malnutrition—Prednisone—multiple sclerosis	0.000101	0.000667	CcSEcCtD
Cladribine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000101	0.000666	CcSEcCtD
Cladribine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000101	0.000665	CcSEcCtD
Cladribine—RRM1—Metabolism—CYP27B1—multiple sclerosis	0.000101	0.00127	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP24A1—multiple sclerosis	0.000101	0.00127	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—RPL5—multiple sclerosis	9.95e-05	0.00125	CbGpPWpGaD
Cladribine—Asthenia—Mitoxantrone—multiple sclerosis	9.93e-05	0.000655	CcSEcCtD
Cladribine—Myalgia—Betamethasone—multiple sclerosis	9.89e-05	0.000652	CcSEcCtD
Cladribine—Myalgia—Dexamethasone—multiple sclerosis	9.89e-05	0.000652	CcSEcCtD
Cladribine—Anxiety—Betamethasone—multiple sclerosis	9.85e-05	0.00065	CcSEcCtD
Cladribine—Anxiety—Dexamethasone—multiple sclerosis	9.85e-05	0.00065	CcSEcCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	9.78e-05	0.00123	CbGpPWpGaD
Cladribine—Discomfort—Betamethasone—multiple sclerosis	9.77e-05	0.000644	CcSEcCtD
Cladribine—Discomfort—Dexamethasone—multiple sclerosis	9.77e-05	0.000644	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—multiple sclerosis	9.76e-05	0.000644	CcSEcCtD
Cladribine—Hypotension—Methylprednisolone—multiple sclerosis	9.74e-05	0.000642	CcSEcCtD
Cladribine—Pain—Prednisolone—multiple sclerosis	9.71e-05	0.000641	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—multiple sclerosis	9.71e-05	0.00064	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—multiple sclerosis	9.64e-05	0.000636	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—multiple sclerosis	9.59e-05	0.000633	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—multiple sclerosis	9.52e-05	0.000628	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	9.52e-05	0.000628	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	9.5e-05	0.000626	CcSEcCtD
Cladribine—Oedema—Dexamethasone—multiple sclerosis	9.48e-05	0.000625	CcSEcCtD
Cladribine—Oedema—Betamethasone—multiple sclerosis	9.48e-05	0.000625	CcSEcCtD
Cladribine—Diarrhoea—Mitoxantrone—multiple sclerosis	9.47e-05	0.000625	CcSEcCtD
Cladribine—Insomnia—Triamcinolone—multiple sclerosis	9.45e-05	0.000623	CcSEcCtD
Cladribine—Insomnia—Methylprednisolone—multiple sclerosis	9.43e-05	0.000622	CcSEcCtD
Cladribine—Infection—Dexamethasone—multiple sclerosis	9.42e-05	0.000621	CcSEcCtD
Cladribine—Infection—Betamethasone—multiple sclerosis	9.42e-05	0.000621	CcSEcCtD
Cladribine—Ill-defined disorder—Prednisone—multiple sclerosis	9.38e-05	0.000619	CcSEcCtD
Cladribine—Paraesthesia—Triamcinolone—multiple sclerosis	9.38e-05	0.000619	CcSEcCtD
Cladribine—Feeling abnormal—Prednisolone—multiple sclerosis	9.36e-05	0.000617	CcSEcCtD
Cladribine—Paraesthesia—Methylprednisolone—multiple sclerosis	9.36e-05	0.000617	CcSEcCtD
Cladribine—Anaemia—Prednisone—multiple sclerosis	9.35e-05	0.000617	CcSEcCtD
Cladribine—Dyspnoea—Triamcinolone—multiple sclerosis	9.31e-05	0.000614	CcSEcCtD
Cladribine—Nervous system disorder—Dexamethasone—multiple sclerosis	9.3e-05	0.000613	CcSEcCtD
Cladribine—Nervous system disorder—Betamethasone—multiple sclerosis	9.3e-05	0.000613	CcSEcCtD
Cladribine—Thrombocytopenia—Dexamethasone—multiple sclerosis	9.28e-05	0.000612	CcSEcCtD
Cladribine—Thrombocytopenia—Betamethasone—multiple sclerosis	9.28e-05	0.000612	CcSEcCtD
Cladribine—Tachycardia—Dexamethasone—multiple sclerosis	9.25e-05	0.00061	CcSEcCtD
Cladribine—Tachycardia—Betamethasone—multiple sclerosis	9.25e-05	0.00061	CcSEcCtD
Cladribine—RRM1—Metabolism—GPC5—multiple sclerosis	9.19e-05	0.00116	CbGpPWpGaD
Cladribine—Erythema multiforme—Methotrexate—multiple sclerosis	9.18e-05	0.000606	CcSEcCtD
Cladribine—Hyperhidrosis—Betamethasone—multiple sclerosis	9.16e-05	0.000604	CcSEcCtD
Cladribine—Hyperhidrosis—Dexamethasone—multiple sclerosis	9.16e-05	0.000604	CcSEcCtD
Cladribine—Malaise—Prednisone—multiple sclerosis	9.12e-05	0.000602	CcSEcCtD
Cladribine—Eye disorder—Methotrexate—multiple sclerosis	9.07e-05	0.000599	CcSEcCtD
Cladribine—RRM2—G1/S Transition—MYC—multiple sclerosis	9.07e-05	0.00114	CbGpPWpGaD
Cladribine—Anorexia—Dexamethasone—multiple sclerosis	9.04e-05	0.000596	CcSEcCtD
Cladribine—Anorexia—Betamethasone—multiple sclerosis	9.04e-05	0.000596	CcSEcCtD
Cladribine—Urticaria—Prednisolone—multiple sclerosis	9.02e-05	0.000595	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—multiple sclerosis	9.01e-05	0.000594	CcSEcCtD
Cladribine—Fatigue—Triamcinolone—multiple sclerosis	9.01e-05	0.000594	CcSEcCtD
Cladribine—Fatigue—Methylprednisolone—multiple sclerosis	8.99e-05	0.000593	CcSEcCtD
Cladribine—Pain—Triamcinolone—multiple sclerosis	8.93e-05	0.000589	CcSEcCtD
Cladribine—Hypotension—Betamethasone—multiple sclerosis	8.86e-05	0.000584	CcSEcCtD
Cladribine—Hypotension—Dexamethasone—multiple sclerosis	8.86e-05	0.000584	CcSEcCtD
Cladribine—Angiopathy—Methotrexate—multiple sclerosis	8.81e-05	0.000581	CcSEcCtD
Cladribine—Vomiting—Mitoxantrone—multiple sclerosis	8.8e-05	0.000581	CcSEcCtD
Cladribine—RRM2B—Metabolism—BCHE—multiple sclerosis	8.79e-05	0.00111	CbGpPWpGaD
Cladribine—Immune system disorder—Methotrexate—multiple sclerosis	8.77e-05	0.000579	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—multiple sclerosis	8.75e-05	0.000577	CcSEcCtD
Cladribine—Rash—Mitoxantrone—multiple sclerosis	8.73e-05	0.000576	CcSEcCtD
Cladribine—Dermatitis—Mitoxantrone—multiple sclerosis	8.72e-05	0.000575	CcSEcCtD
Cladribine—Chills—Methotrexate—multiple sclerosis	8.71e-05	0.000575	CcSEcCtD
Cladribine—POLE—G1/S Transition—MYC—multiple sclerosis	8.7e-05	0.0011	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	8.69e-05	0.00109	CbGpPWpGaD
Cladribine—Headache—Mitoxantrone—multiple sclerosis	8.67e-05	0.000572	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	8.64e-05	0.00057	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	8.64e-05	0.00057	CcSEcCtD
Cladribine—Arthralgia—Prednisone—multiple sclerosis	8.61e-05	0.000568	CcSEcCtD
Cladribine—Myalgia—Prednisone—multiple sclerosis	8.61e-05	0.000568	CcSEcCtD
Cladribine—Feeling abnormal—Triamcinolone—multiple sclerosis	8.61e-05	0.000568	CcSEcCtD
Cladribine—Feeling abnormal—Methylprednisolone—multiple sclerosis	8.59e-05	0.000567	CcSEcCtD
Cladribine—Anxiety—Prednisone—multiple sclerosis	8.58e-05	0.000566	CcSEcCtD
Cladribine—Alopecia—Methotrexate—multiple sclerosis	8.58e-05	0.000566	CcSEcCtD
Cladribine—Insomnia—Betamethasone—multiple sclerosis	8.57e-05	0.000565	CcSEcCtD
Cladribine—Insomnia—Dexamethasone—multiple sclerosis	8.57e-05	0.000565	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	8.55e-05	0.000564	CcSEcCtD
Cladribine—POLA1—E2F transcription factor network—MYC—multiple sclerosis	8.55e-05	0.00108	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	8.52e-05	0.000562	CcSEcCtD
Cladribine—Paraesthesia—Dexamethasone—multiple sclerosis	8.51e-05	0.000561	CcSEcCtD
Cladribine—Paraesthesia—Betamethasone—multiple sclerosis	8.51e-05	0.000561	CcSEcCtD
Cladribine—Discomfort—Prednisone—multiple sclerosis	8.51e-05	0.000561	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—multiple sclerosis	8.51e-05	0.000561	CcSEcCtD
Cladribine—Erythema—Methotrexate—multiple sclerosis	8.45e-05	0.000558	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—multiple sclerosis	8.45e-05	0.000558	CcSEcCtD
Cladribine—Hypersensitivity—Prednisolone—multiple sclerosis	8.37e-05	0.000552	CcSEcCtD
Cladribine—DCK—Desoximetasone—Methylprednisolone—multiple sclerosis	8.35e-05	0.0206	CbGdCrCtD
Cladribine—Urticaria—Triamcinolone—multiple sclerosis	8.3e-05	0.000547	CcSEcCtD
Cladribine—Urticaria—Methylprednisolone—multiple sclerosis	8.28e-05	0.000546	CcSEcCtD
Cladribine—RRM2—Metabolism—CYP24A1—multiple sclerosis	8.28e-05	0.00104	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP27B1—multiple sclerosis	8.28e-05	0.00104	CbGpPWpGaD
Cladribine—Body temperature increased—Triamcinolone—multiple sclerosis	8.26e-05	0.000545	CcSEcCtD
Cladribine—Oedema—Prednisone—multiple sclerosis	8.25e-05	0.000544	CcSEcCtD
Cladribine—Abdominal pain—Methylprednisolone—multiple sclerosis	8.24e-05	0.000543	CcSEcCtD
Cladribine—Decreased appetite—Dexamethasone—multiple sclerosis	8.24e-05	0.000543	CcSEcCtD
Cladribine—Decreased appetite—Betamethasone—multiple sclerosis	8.24e-05	0.000543	CcSEcCtD
Cladribine—Nausea—Mitoxantrone—multiple sclerosis	8.22e-05	0.000542	CcSEcCtD
Cladribine—DCK—Desoximetasone—Dexamethasone—multiple sclerosis	8.22e-05	0.0203	CbGdCrCtD
Cladribine—DCK—Desoximetasone—Betamethasone—multiple sclerosis	8.22e-05	0.0203	CbGdCrCtD
Cladribine—Infection—Prednisone—multiple sclerosis	8.2e-05	0.000541	CcSEcCtD
Cladribine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	8.18e-05	0.00054	CcSEcCtD
Cladribine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	8.18e-05	0.00054	CcSEcCtD
Cladribine—Back pain—Methotrexate—multiple sclerosis	8.18e-05	0.000539	CcSEcCtD
Cladribine—Fatigue—Betamethasone—multiple sclerosis	8.17e-05	0.000539	CcSEcCtD
Cladribine—Fatigue—Dexamethasone—multiple sclerosis	8.17e-05	0.000539	CcSEcCtD
Cladribine—DCK—Diflorasone—Methylprednisolone—multiple sclerosis	8.11e-05	0.02	CbGdCrCtD
Cladribine—Pain—Dexamethasone—multiple sclerosis	8.11e-05	0.000535	CcSEcCtD
Cladribine—Pain—Betamethasone—multiple sclerosis	8.11e-05	0.000535	CcSEcCtD
Cladribine—Nervous system disorder—Prednisone—multiple sclerosis	8.1e-05	0.000534	CcSEcCtD
Cladribine—Tachycardia—Prednisone—multiple sclerosis	8.06e-05	0.000531	CcSEcCtD
Cladribine—DCK—Desoximetasone—Triamcinolone—multiple sclerosis	8.03e-05	0.0198	CbGdCrCtD
Cladribine—Skin disorder—Prednisone—multiple sclerosis	8.02e-05	0.000529	CcSEcCtD
Cladribine—Hyperhidrosis—Prednisone—multiple sclerosis	7.98e-05	0.000526	CcSEcCtD
Cladribine—DCK—Diflorasone—Dexamethasone—multiple sclerosis	7.98e-05	0.0197	CbGdCrCtD
Cladribine—DCK—Diflorasone—Betamethasone—multiple sclerosis	7.98e-05	0.0197	CbGdCrCtD
Cladribine—POLE—S Phase—MYC—multiple sclerosis	7.9e-05	0.000995	CbGpPWpGaD
Cladribine—Anorexia—Prednisone—multiple sclerosis	7.87e-05	0.000519	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—multiple sclerosis	7.84e-05	0.000517	CcSEcCtD
Cladribine—NR5A1—Gene Expression—PGR—multiple sclerosis	7.83e-05	0.000986	CbGpPWpGaD
Cladribine—Anaemia—Methotrexate—multiple sclerosis	7.81e-05	0.000515	CcSEcCtD
Cladribine—Feeling abnormal—Dexamethasone—multiple sclerosis	7.81e-05	0.000515	CcSEcCtD
Cladribine—Feeling abnormal—Betamethasone—multiple sclerosis	7.81e-05	0.000515	CcSEcCtD
Cladribine—DCK—Diflorasone—Triamcinolone—multiple sclerosis	7.8e-05	0.0192	CbGdCrCtD
Cladribine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	7.75e-05	0.000511	CcSEcCtD
Cladribine—Gastrointestinal pain—Betamethasone—multiple sclerosis	7.75e-05	0.000511	CcSEcCtD
Cladribine—DCK—Metabolism—CYP24A1—multiple sclerosis	7.74e-05	0.000974	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP27B1—multiple sclerosis	7.74e-05	0.000974	CbGpPWpGaD
Cladribine—Hypersensitivity—Triamcinolone—multiple sclerosis	7.7e-05	0.000508	CcSEcCtD
Cladribine—Hypersensitivity—Methylprednisolone—multiple sclerosis	7.68e-05	0.000507	CcSEcCtD
Cladribine—RRM2—Mitotic G1-G1/S phases—MYC—multiple sclerosis	7.64e-05	0.000962	CbGpPWpGaD
Cladribine—Malaise—Methotrexate—multiple sclerosis	7.62e-05	0.000503	CcSEcCtD
Cladribine—DCK—Desoximetasone—Prednisone—multiple sclerosis	7.62e-05	0.0188	CbGdCrCtD
Cladribine—PNP—Metabolism—BCHE—multiple sclerosis	7.62e-05	0.000959	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GPC5—multiple sclerosis	7.57e-05	0.000953	CbGpPWpGaD
Cladribine—Urticaria—Dexamethasone—multiple sclerosis	7.53e-05	0.000497	CcSEcCtD
Cladribine—Urticaria—Betamethasone—multiple sclerosis	7.53e-05	0.000497	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	7.52e-05	0.000496	CcSEcCtD
Cladribine—Dizziness—Prednisolone—multiple sclerosis	7.51e-05	0.000495	CcSEcCtD
Cladribine—Asthenia—Triamcinolone—multiple sclerosis	7.5e-05	0.000494	CcSEcCtD
Cladribine—Abdominal pain—Betamethasone—multiple sclerosis	7.49e-05	0.000494	CcSEcCtD
Cladribine—Abdominal pain—Dexamethasone—multiple sclerosis	7.49e-05	0.000494	CcSEcCtD
Cladribine—Body temperature increased—Betamethasone—multiple sclerosis	7.49e-05	0.000494	CcSEcCtD
Cladribine—Body temperature increased—Dexamethasone—multiple sclerosis	7.49e-05	0.000494	CcSEcCtD
Cladribine—Asthenia—Methylprednisolone—multiple sclerosis	7.48e-05	0.000493	CcSEcCtD
Cladribine—Insomnia—Prednisone—multiple sclerosis	7.47e-05	0.000492	CcSEcCtD
Cladribine—DCK—Desoximetasone—Prednisolone—multiple sclerosis	7.44e-05	0.0184	CbGdCrCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	7.43e-05	0.000935	CbGpPWpGaD
Cladribine—Paraesthesia—Prednisone—multiple sclerosis	7.41e-05	0.000489	CcSEcCtD
Cladribine—DCK—Diflorasone—Prednisone—multiple sclerosis	7.4e-05	0.0183	CbGdCrCtD
Cladribine—Pruritus—Triamcinolone—multiple sclerosis	7.39e-05	0.000488	CcSEcCtD
Cladribine—Cough—Methotrexate—multiple sclerosis	7.38e-05	0.000487	CcSEcCtD
Cladribine—Pruritus—Methylprednisolone—multiple sclerosis	7.37e-05	0.000486	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—MYC—multiple sclerosis	7.33e-05	0.000923	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	7.33e-05	0.000923	CbGpPWpGaD
Cladribine—DCK—Diflorasone—Prednisolone—multiple sclerosis	7.22e-05	0.0178	CbGdCrCtD
Cladribine—Myalgia—Methotrexate—multiple sclerosis	7.2e-05	0.000475	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—multiple sclerosis	7.2e-05	0.000475	CcSEcCtD
Cladribine—Chest pain—Methotrexate—multiple sclerosis	7.2e-05	0.000475	CcSEcCtD
Cladribine—Decreased appetite—Prednisone—multiple sclerosis	7.18e-05	0.000473	CcSEcCtD
Cladribine—Rash—Prednisolone—multiple sclerosis	7.16e-05	0.000472	CcSEcCtD
Cladribine—Dermatitis—Prednisolone—multiple sclerosis	7.16e-05	0.000472	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	7.15e-05	0.000471	CcSEcCtD
Cladribine—Diarrhoea—Methylprednisolone—multiple sclerosis	7.13e-05	0.00047	CcSEcCtD
Cladribine—Fatigue—Prednisone—multiple sclerosis	7.12e-05	0.000469	CcSEcCtD
Cladribine—Headache—Prednisolone—multiple sclerosis	7.12e-05	0.000469	CcSEcCtD
Cladribine—Discomfort—Methotrexate—multiple sclerosis	7.11e-05	0.000469	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	7.11e-05	0.000895	CbGpPWpGaD
Cladribine—DCK—Metabolism—GPC5—multiple sclerosis	7.07e-05	0.000891	CbGpPWpGaD
Cladribine—Constipation—Prednisone—multiple sclerosis	7.06e-05	0.000466	CcSEcCtD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	7.04e-05	0.000886	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	7.03e-05	0.000885	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	7.01e-05	0.000883	CbGpPWpGaD
Cladribine—Confusional state—Methotrexate—multiple sclerosis	6.96e-05	0.000459	CcSEcCtD
Cladribine—SLC22A2—Transmission across Chemical Synapses—BCHE—multiple sclerosis	6.91e-05	0.00087	CbGpPWpGaD
Cladribine—Dizziness—Triamcinolone—multiple sclerosis	6.91e-05	0.000456	CcSEcCtD
Cladribine—Dizziness—Methylprednisolone—multiple sclerosis	6.89e-05	0.000455	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	6.88e-05	0.000866	CbGpPWpGaD
Cladribine—Infection—Methotrexate—multiple sclerosis	6.85e-05	0.000452	CcSEcCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	6.83e-05	0.000861	CbGpPWpGaD
Cladribine—Feeling abnormal—Prednisone—multiple sclerosis	6.8e-05	0.000449	CcSEcCtD
Cladribine—Asthenia—Betamethasone—multiple sclerosis	6.8e-05	0.000449	CcSEcCtD
Cladribine—Asthenia—Dexamethasone—multiple sclerosis	6.8e-05	0.000449	CcSEcCtD
Cladribine—Nervous system disorder—Methotrexate—multiple sclerosis	6.77e-05	0.000446	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—multiple sclerosis	6.75e-05	0.000446	CcSEcCtD
Cladribine—Gastrointestinal pain—Prednisone—multiple sclerosis	6.75e-05	0.000445	CcSEcCtD
Cladribine—Nausea—Prednisolone—multiple sclerosis	6.75e-05	0.000445	CcSEcCtD
Cladribine—Pruritus—Betamethasone—multiple sclerosis	6.71e-05	0.000442	CcSEcCtD
Cladribine—Pruritus—Dexamethasone—multiple sclerosis	6.71e-05	0.000442	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—multiple sclerosis	6.7e-05	0.000442	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—multiple sclerosis	6.67e-05	0.00044	CcSEcCtD
Cladribine—Vomiting—Triamcinolone—multiple sclerosis	6.64e-05	0.000438	CcSEcCtD
Cladribine—Vomiting—Methylprednisolone—multiple sclerosis	6.63e-05	0.000437	CcSEcCtD
Cladribine—Rash—Triamcinolone—multiple sclerosis	6.59e-05	0.000434	CcSEcCtD
Cladribine—Dermatitis—Triamcinolone—multiple sclerosis	6.58e-05	0.000434	CcSEcCtD
Cladribine—Anorexia—Methotrexate—multiple sclerosis	6.58e-05	0.000434	CcSEcCtD
Cladribine—Rash—Methylprednisolone—multiple sclerosis	6.57e-05	0.000433	CcSEcCtD
Cladribine—Dermatitis—Methylprednisolone—multiple sclerosis	6.57e-05	0.000433	CcSEcCtD
Cladribine—Urticaria—Prednisone—multiple sclerosis	6.56e-05	0.000433	CcSEcCtD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	6.56e-05	0.000826	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	6.55e-05	0.000824	CbGpPWpGaD
Cladribine—Headache—Triamcinolone—multiple sclerosis	6.54e-05	0.000432	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—TYK2—multiple sclerosis	6.54e-05	0.000823	CbGpPWpGaD
Cladribine—Headache—Methylprednisolone—multiple sclerosis	6.53e-05	0.000431	CcSEcCtD
Cladribine—Abdominal pain—Prednisone—multiple sclerosis	6.53e-05	0.00043	CcSEcCtD
Cladribine—Body temperature increased—Prednisone—multiple sclerosis	6.53e-05	0.00043	CcSEcCtD
Cladribine—Diarrhoea—Betamethasone—multiple sclerosis	6.49e-05	0.000428	CcSEcCtD
Cladribine—Diarrhoea—Dexamethasone—multiple sclerosis	6.49e-05	0.000428	CcSEcCtD
Cladribine—Hypotension—Methotrexate—multiple sclerosis	6.45e-05	0.000425	CcSEcCtD
Cladribine—SLC22A1—Transmission across Chemical Synapses—BCHE—multiple sclerosis	6.44e-05	0.000811	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	6.43e-05	0.000809	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	6.29e-05	0.000415	CcSEcCtD
Cladribine—RRM2—Metabolism—RRM1—multiple sclerosis	6.27e-05	0.00079	CbGpPWpGaD
Cladribine—Dizziness—Dexamethasone—multiple sclerosis	6.27e-05	0.000413	CcSEcCtD
Cladribine—Dizziness—Betamethasone—multiple sclerosis	6.27e-05	0.000413	CcSEcCtD
Cladribine—Insomnia—Methotrexate—multiple sclerosis	6.24e-05	0.000412	CcSEcCtD
Cladribine—Nausea—Triamcinolone—multiple sclerosis	6.21e-05	0.000409	CcSEcCtD
Cladribine—POLA1—G1/S Transition—MYC—multiple sclerosis	6.2e-05	0.000781	CbGpPWpGaD
Cladribine—Paraesthesia—Methotrexate—multiple sclerosis	6.19e-05	0.000409	CcSEcCtD
Cladribine—Nausea—Methylprednisolone—multiple sclerosis	6.19e-05	0.000408	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—multiple sclerosis	6.15e-05	0.000406	CcSEcCtD
Cladribine—Somnolence—Methotrexate—multiple sclerosis	6.13e-05	0.000405	CcSEcCtD
Cladribine—Hypersensitivity—Prednisone—multiple sclerosis	6.08e-05	0.000401	CcSEcCtD
Cladribine—Vomiting—Dexamethasone—multiple sclerosis	6.03e-05	0.000398	CcSEcCtD
Cladribine—Vomiting—Betamethasone—multiple sclerosis	6.03e-05	0.000398	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—multiple sclerosis	6e-05	0.000396	CcSEcCtD
Cladribine—Rash—Betamethasone—multiple sclerosis	5.98e-05	0.000394	CcSEcCtD
Cladribine—Rash—Dexamethasone—multiple sclerosis	5.98e-05	0.000394	CcSEcCtD
Cladribine—Dermatitis—Dexamethasone—multiple sclerosis	5.97e-05	0.000394	CcSEcCtD
Cladribine—Dermatitis—Betamethasone—multiple sclerosis	5.97e-05	0.000394	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	5.96e-05	0.000393	CcSEcCtD
Cladribine—Fatigue—Methotrexate—multiple sclerosis	5.95e-05	0.000392	CcSEcCtD
Cladribine—Headache—Betamethasone—multiple sclerosis	5.94e-05	0.000392	CcSEcCtD
Cladribine—Headache—Dexamethasone—multiple sclerosis	5.94e-05	0.000392	CcSEcCtD
Cladribine—Asthenia—Prednisone—multiple sclerosis	5.92e-05	0.000391	CcSEcCtD
Cladribine—Pain—Methotrexate—multiple sclerosis	5.9e-05	0.000389	CcSEcCtD
Cladribine—DCK—Metabolism—RRM1—multiple sclerosis	5.86e-05	0.000738	CbGpPWpGaD
Cladribine—Pruritus—Prednisone—multiple sclerosis	5.84e-05	0.000385	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—multiple sclerosis	5.69e-05	0.000375	CcSEcCtD
Cladribine—Diarrhoea—Prednisone—multiple sclerosis	5.65e-05	0.000373	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—multiple sclerosis	5.64e-05	0.000372	CcSEcCtD
Cladribine—Nausea—Betamethasone—multiple sclerosis	5.63e-05	0.000371	CcSEcCtD
Cladribine—Nausea—Dexamethasone—multiple sclerosis	5.63e-05	0.000371	CcSEcCtD
Cladribine—POLA1—S Phase—MYC—multiple sclerosis	5.63e-05	0.000709	CbGpPWpGaD
Cladribine—Urticaria—Methotrexate—multiple sclerosis	5.48e-05	0.000361	CcSEcCtD
Cladribine—NR5A1—Gene Expression—VDR—multiple sclerosis	5.47e-05	0.000689	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—MAPK1—multiple sclerosis	5.46e-05	0.000687	CbGpPWpGaD
Cladribine—Dizziness—Prednisone—multiple sclerosis	5.46e-05	0.00036	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—multiple sclerosis	5.45e-05	0.00036	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—multiple sclerosis	5.45e-05	0.00036	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—ALB—multiple sclerosis	5.4e-05	0.00068	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.39e-05	0.000678	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.33e-05	0.000671	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—BCHE—multiple sclerosis	5.3e-05	0.000667	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—APOE—multiple sclerosis	5.29e-05	0.000666	CbGpPWpGaD
Cladribine—Vomiting—Prednisone—multiple sclerosis	5.25e-05	0.000346	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—MYC—multiple sclerosis	5.23e-05	0.000658	CbGpPWpGaD
Cladribine—Rash—Prednisone—multiple sclerosis	5.2e-05	0.000343	CcSEcCtD
Cladribine—Dermatitis—Prednisone—multiple sclerosis	5.2e-05	0.000343	CcSEcCtD
Cladribine—Headache—Prednisone—multiple sclerosis	5.17e-05	0.000341	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—MMP9—multiple sclerosis	5.15e-05	0.000648	CbGpPWpGaD
Cladribine—Hypersensitivity—Methotrexate—multiple sclerosis	5.08e-05	0.000335	CcSEcCtD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	4.97e-05	0.000626	CbGpPWpGaD
Cladribine—Asthenia—Methotrexate—multiple sclerosis	4.95e-05	0.000326	CcSEcCtD
Cladribine—SLC22A1—Neuronal System—BCHE—multiple sclerosis	4.94e-05	0.000621	CbGpPWpGaD
Cladribine—Nausea—Prednisone—multiple sclerosis	4.9e-05	0.000323	CcSEcCtD
Cladribine—Pruritus—Methotrexate—multiple sclerosis	4.88e-05	0.000322	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—multiple sclerosis	4.72e-05	0.000311	CcSEcCtD
Cladribine—PNP—Metabolism—APOE—multiple sclerosis	4.58e-05	0.000577	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—STAT3—multiple sclerosis	4.58e-05	0.000576	CbGpPWpGaD
Cladribine—Dizziness—Methotrexate—multiple sclerosis	4.56e-05	0.000301	CcSEcCtD
Cladribine—RRM2B—Metabolism—POMC—multiple sclerosis	4.54e-05	0.000572	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—multiple sclerosis	4.52e-05	0.000569	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SRM—multiple sclerosis	4.39e-05	0.000553	CbGpPWpGaD
Cladribine—Vomiting—Methotrexate—multiple sclerosis	4.39e-05	0.000289	CcSEcCtD
Cladribine—RRM1—Metabolism—BCHE—multiple sclerosis	4.38e-05	0.000551	CbGpPWpGaD
Cladribine—Rash—Methotrexate—multiple sclerosis	4.35e-05	0.000287	CcSEcCtD
Cladribine—SLC22A2—Metabolism—SRM—multiple sclerosis	4.35e-05	0.000548	CbGpPWpGaD
Cladribine—Dermatitis—Methotrexate—multiple sclerosis	4.35e-05	0.000287	CcSEcCtD
Cladribine—Headache—Methotrexate—multiple sclerosis	4.32e-05	0.000285	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.26e-05	0.000536	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TGFB1—multiple sclerosis	4.24e-05	0.000534	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.21e-05	0.000531	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—multiple sclerosis	4.17e-05	0.000526	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MAPK1—multiple sclerosis	4.16e-05	0.000524	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—ALB—multiple sclerosis	4.14e-05	0.000521	CbGpPWpGaD
Cladribine—Nausea—Methotrexate—multiple sclerosis	4.1e-05	0.00027	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	4.08e-05	0.000514	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SRM—multiple sclerosis	4.05e-05	0.00051	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TNF—multiple sclerosis	3.96e-05	0.000499	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.96e-05	0.000498	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.95e-05	0.000497	CbGpPWpGaD
Cladribine—PNP—Metabolism—POMC—multiple sclerosis	3.94e-05	0.000496	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.93e-05	0.000495	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.87e-05	0.000488	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.76e-05	0.000474	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MYC—multiple sclerosis	3.73e-05	0.00047	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.73e-05	0.000469	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.69e-05	0.000464	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MAPK1—multiple sclerosis	3.65e-05	0.00046	CbGpPWpGaD
Cladribine—RRM2—Metabolism—BCHE—multiple sclerosis	3.6e-05	0.000454	CbGpPWpGaD
Cladribine—PNP—Metabolism—ALB—multiple sclerosis	3.59e-05	0.000452	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—MAPK1—multiple sclerosis	3.52e-05	0.000443	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.47e-05	0.000437	CbGpPWpGaD
Cladribine—DCK—Metabolism—BCHE—multiple sclerosis	3.37e-05	0.000424	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—IL6—multiple sclerosis	3.2e-05	0.000403	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP24A1—multiple sclerosis	3.1e-05	0.00039	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP27B1—multiple sclerosis	3.1e-05	0.00039	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP27B1—multiple sclerosis	3.06e-05	0.000386	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP24A1—multiple sclerosis	3.06e-05	0.000386	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP24A1—multiple sclerosis	2.86e-05	0.00036	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP27B1—multiple sclerosis	2.86e-05	0.00036	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GPC5—multiple sclerosis	2.83e-05	0.000357	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GPC5—multiple sclerosis	2.8e-05	0.000353	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—multiple sclerosis	2.8e-05	0.000353	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	2.74e-05	0.000345	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—multiple sclerosis	2.69e-05	0.000339	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.64e-05	0.000332	CbGpPWpGaD
Cladribine—RRM1—Metabolism—APOE—multiple sclerosis	2.63e-05	0.000331	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	2.63e-05	0.000331	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GPC5—multiple sclerosis	2.61e-05	0.000329	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAPK1—multiple sclerosis	2.51e-05	0.000316	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—multiple sclerosis	2.51e-05	0.000315	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.46e-05	0.00031	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAPK1—multiple sclerosis	2.45e-05	0.000309	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—multiple sclerosis	2.4e-05	0.000303	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MAPK1—multiple sclerosis	2.35e-05	0.000296	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—RRM1—multiple sclerosis	2.35e-05	0.000295	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—RRM1—multiple sclerosis	2.32e-05	0.000292	CbGpPWpGaD
Cladribine—RRM1—Metabolism—POMC—multiple sclerosis	2.26e-05	0.000285	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—multiple sclerosis	2.18e-05	0.000274	CbGpPWpGaD
Cladribine—RRM2—Metabolism—APOE—multiple sclerosis	2.17e-05	0.000273	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—RRM1—multiple sclerosis	2.16e-05	0.000272	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ALB—multiple sclerosis	2.06e-05	0.00026	CbGpPWpGaD
Cladribine—DCK—Metabolism—APOE—multiple sclerosis	2.03e-05	0.000255	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	2.02e-05	0.000254	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—multiple sclerosis	1.92e-05	0.000241	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	1.88e-05	0.000237	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	1.87e-05	0.000236	CbGpPWpGaD
Cladribine—RRM2—Metabolism—POMC—multiple sclerosis	1.86e-05	0.000234	CbGpPWpGaD
Cladribine—DCK—Metabolism—POMC—multiple sclerosis	1.74e-05	0.000219	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—multiple sclerosis	1.71e-05	0.000216	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ALB—multiple sclerosis	1.7e-05	0.000214	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK1—multiple sclerosis	1.68e-05	0.000211	CbGpPWpGaD
Cladribine—DCK—Metabolism—ALB—multiple sclerosis	1.59e-05	0.0002	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—MAPK1—multiple sclerosis	1.55e-05	0.000195	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MAPK1—multiple sclerosis	1.44e-05	0.000182	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.36e-05	0.000171	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—BCHE—multiple sclerosis	1.35e-05	0.00017	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.34e-05	0.000169	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—BCHE—multiple sclerosis	1.33e-05	0.000168	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.25e-05	0.000157	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—BCHE—multiple sclerosis	1.24e-05	0.000157	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—APOE—multiple sclerosis	8.11e-06	0.000102	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—APOE—multiple sclerosis	8.02e-06	0.000101	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—APOE—multiple sclerosis	7.48e-06	9.42e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—POMC—multiple sclerosis	6.96e-06	8.77e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—POMC—multiple sclerosis	6.89e-06	8.68e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—POMC—multiple sclerosis	6.42e-06	8.09e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALB—multiple sclerosis	6.35e-06	7.99e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALB—multiple sclerosis	6.28e-06	7.91e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALB—multiple sclerosis	5.86e-06	7.37e-05	CbGpPWpGaD
